Vall d’Hebron University Hospital and the biotechnology company Goodgut, a HIPRA group company, both CataloniaBio  & HealthTech members, are launching a study to implement RAID-Dx, a non-invasive diagnostic test for irritable bowel syndrome (IBS). The study will be conducted with 300 patients with symptoms of the disease.

Aiming to create artificial organs and tissues for clinical application, the Production  and Validation Center for Advanced Therapies of the University of Barcelona (Creatio), will purchase and launch one of the first 4D laser-assisted  bioprinters in Europe. Creatio obtained a funding of 999,604 euros from the Ministry of Science and Innovation, within the call Equipamiento Científico-Técnico 2021. The University of Barcelona will become a worldwide reference in translational research in tissue engineering.

MOWWOT, a company specializing in medical devices for intestinal transit disorder, and a member of CataloniaBio &  HealthTech, has announced the closure of the first tranche of its Series  A investment round worth 1.05 million euros. This first tranche has involved USM Global Corporation, an investment vehicle that brings together several crowdfunding investors from Capital Cell, ENISA, 4M Medical GmbH and other German business angels.

Vytrus Biotech, a company specializing in active ingredients derived from plant stem cells for the cosmetics industry, and a CataloniaBio &  HealthTech member, went public this Tuesday, March 15 and closed its  first day with an increase in its value by more than 25% in its first trading  day on BME Growth, the SME exchange.

Specipig, a CataloniaBio & HealthTechmember, closed 2021 achieving 150 preclinical research projects andreinforcing its position as the reference preclinical ContractResearch Organisation (CRO) for the globalpharmaceutical, biotechnology and medical technology industry.

CataloniaBio & HealthTech s’adhereix al Parc Científic de Barcelona i a diverses entitats ubicades al PCB en l’emissió del següent comunicat en suport al poble ucraïnès davant la invasió de Rússia.

The 2022 edition of the Mobile World Congress (MWC) is beginning to pick up the pre-pandemic pace. Still with the mask as a constant reminder, this year's edition of the MWC has closed its doors with more than 60,000 attendees from nearly 200 different countries, figures that have exceeded the organization's initial scenario.

Ysios Capital, gestora europea de venture capital al sector de les ciències de la vida, membre de CataloniaBio & HealthTech, ha anunciat el nomenament de Thomas Harth com a Principal. Thomas se suma a Ysios per reforçar l’equip d’anàlisi i identificació de noves inversions. En el rol de Principal també representarà els interessos dels fons d’Ysios als consells d’administració de les companyies participades.

Accure Therapeutics, a privatetranslational neuroscience R&D company and a CataloniaBio & HealthTechmember, and Oculis, a globalophthalmology company developing life changing treatments to save sight andimprove eye care with breakthrough innovations, announced a licensing agreementgranting Oculis exclusive global rights to develop and commercialize ACT-01 apotentially disease modifying therapy to protect and prevent damage to theoptic nerve and retina.

GENOMCORE S.L., also known for its line of personalized health services under the MADE OF GENES brand, has received funding for the largest funded artificial  intelligence project to personalize the treatment of metastatic cancer. The project is funded by the European Union within the Next Generation EU program, which will cover approximately 7.5 million euros of the consortium's overall budget (10,692,931 euros), of which GENOMCORE will receive 919,610.22 euros  from the funds which accounts for 80% of the total budget.

Inveready has acquired the majority of one of the leading value fund managers in Spain, True Value Investments, SGIIC, S.A. With this operation, Inveready enters the market of mutual funds with the help of a team recognized in the sector. The financial group has reached a binding agreement and is only subject to the mandatory authorization by CNMV, for the acquisition of the capital of True Value Investments, which manages more than € 300 million.

The startup specializing in digital health solutions, and a CataloniaBio & HealthTech  member, has closed a € 1.3 million round led by the Swiss Board Advisors AG and Viopas Venture Consulting GmbH, two European funds specializing in the healthcare sector. Both have joined the company as minority partners and the funds will be used by the company to consolidate in Spain and expand into Europe.

Asabys Partners, gestora de capital risc especialitzada en biomedicina, membre de CataloniaBio & HealthTech, eleva el seu primer fons fins els 117 milions d’euros. L’ampliació del vehicle Sabadell Asabys, amb el tancament situat a 87 milions, és degut a una inversió de 30 milions del Fons Europeu d’Inversions (FEI).

This morning, CataloniaBio  & HealthTech formally renewed its Board of Directors at the Generally Assembly of members, which was held today in the MGS auditorium in Barcelona. This replacement comes after the previous Board of Directors, led by per Jaume Amat (Specipig), completed its 4 year term as per the association’s charter.

Integra Therapeutics, a biotechnology company that is creating next-generation gene writing tools, announced today the appointment of Professor George Church to its Scientific Advisory Board (SAB).

The Institute of  Bioengineering of Catalonia (IBEC) hosted the presentation of the Strategic Research Program in biotechnology applied to health, developed through the so-called Complementary Plans of the Recovery and Resilience Mechanism, and which will be executed until the end of 2024. It has a budget of 32 million euros and 5 autonomous communities will work together, co-financing the program.

CataloniaBio& HealthTech have launched the IVD Accelerator Programme, with the support of ACCIÓ (Generalitat de Catalunya), to boost projects from In VitroDiagnostics (IVD) companies, providing specialist assistance and training in key areas such as evaluation of technologies, related regulatory issues and market access strategies, among others.

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies and a CataloniaBio & HealthTech member, today announced the completion  of an oversubscribed €50 million series A financing. The financing was co-led by UCB Ventures and existing shareholder Ysios Capital and joined by new investors New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners. The Company was seeded in 2020 by Ysios Capital and Asabys Partners, both CataloniaBio & HealthTech members.

CataloniaBio& HealthTech is launching the eight edition of its Biosuccess Award, an initiative that will recognise the best business milestone of 2021 in the health and life sciences sector in Catalonia. The deadline for submitting candidacies is 28 February, using this form.

The winner will receive an honorific award that this year will be given, again, during the CataloniaBio & HealthTech Gala, the benchmark annual event for the biomedicine and health sector in Catalonia, bringing together over 200 entrepreneurs, executives, researchers, politicians and public figures. The Gala, that had to be cancelled on 2020 due to the pandemic, is going ...

Wivi Visión, a company specializing in solutions that assess the capabilities of the visual system, has signed an agreement with the General Óptica group for its presence in its stores. The companies have signed a collaboration agreement in which they will begin the  development of their technology aimed at the assessment and treatment of visual  dysfunctions in the chain's establishments. During the first phase of the Wivi Visión project, it will be set up in an initial group of four stores in Madrid, Barcelona, Vigo and Jerez de la Frontera.

The Wivi Vision system performs a visual cognitive assessment to ...